Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angélique Da Silva

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Bulletin Du Cancer|January 31, 2022
[New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer]Rayan Kabirian, Angélique Da Silva
JAMA Oncology|September 24, 2020
Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge-ReplyCharles Dolladille, Angélique Da-Silva, Joachim Alexandre
The Breast Journal|October 24, 2020
Abemaciclib-induced reversible grade 4 nephrotoxicityAngélique Da Silva, Basile Chretien, Joachim Alexandre, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 9, 2024
Baseline and early <sup>18</sup>F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapyCharline Lasnon, Adeline Morel, Nicolas Aide, et al.
JAMA Oncology|October 14, 2021
Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A Pharmacoepidemiologic StudyPierre-Marie Morice, Basile Chrétien, Angélique Da Silva, et al.
BMJ Open|December 3, 2024
Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signalsJean-Matthieu L'Orphelin, Angélique Da Silva, Jean Cabon, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2025
Pazopanib and antacids: insights from the WHO pharmacovigilance databaseKazuki Nishida, Yao Liang, Osamu Maeda, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2024
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancerFrançois Cherifi, Angélique Da Silva, Diogo Martins-Branco, et al.
Journal of Neurology|December 16, 2025
Guillain-Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance studyJean Cabon, Mathilde Ducloie, Basile Chretien, et al.
Therapie|January 24, 2025
BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort studyEmilien Ezine, Angélique Da Silva, Safa Idoudi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Bulletin Du Cancer|January 31, 2022
[New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer]Rayan Kabirian, Angélique Da Silva
JAMA Oncology|September 24, 2020
Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge-ReplyCharles Dolladille, Angélique Da-Silva, Joachim Alexandre
The Breast Journal|October 24, 2020
Abemaciclib-induced reversible grade 4 nephrotoxicityAngélique Da Silva, Basile Chretien, Joachim Alexandre, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|July 9, 2024
Baseline and early <sup>18</sup>F-FDG PET/CT evaluations as predictors of progression-free survival in metastatic breast cancer patients treated with targeted anti-CDK therapyCharline Lasnon, Adeline Morel, Nicolas Aide, et al.
JAMA Oncology|October 14, 2021
Occurrence of Pancytopenia Among Patients With Cancer Treated With Poly(Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A Pharmacoepidemiologic StudyPierre-Marie Morice, Basile Chrétien, Angélique Da Silva, et al.
BMJ Open|December 3, 2024
Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signalsJean-Matthieu L'Orphelin, Angélique Da Silva, Jean Cabon, et al.
Cancer Chemotherapy and Pharmacology|July 2, 2025
Pazopanib and antacids: insights from the WHO pharmacovigilance databaseKazuki Nishida, Yao Liang, Osamu Maeda, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 12, 2024
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancerFrançois Cherifi, Angélique Da Silva, Diogo Martins-Branco, et al.
Journal of Neurology|December 16, 2025
Guillain-Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance studyJean Cabon, Mathilde Ducloie, Basile Chretien, et al.
Therapie|January 24, 2025
BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort studyEmilien Ezine, Angélique Da Silva, Safa Idoudi, et al.
Pageof 3